MENU
+Compare
BIIB
Stock ticker: NASDAQ
AS OF
Jul 10, 04:59 PM (EDT)
Price
$135.33
Change
+$2.31 (+1.74%)
Capitalization
31.34B

BIIB Biogen Forecast, Technical & Fundamental Analysis

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan... Show more

Industry: #Biotechnology
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for BIIB with price predictions
Jul 09, 2025

Momentum Indicator for BIIB turns positive, indicating new upward trend

BIIB saw its Momentum Indicator move above the 0 level on July 02, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for BIIB just turned positive on July 02, 2025. Looking at past instances where BIIB's MACD turned positive, the stock continued to rise in of 55 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BIIB advanced for three days, in of 257 cases, the price rose further within the following month. The odds of a continued upward trend are .

BIIB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 138 cases where BIIB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIIB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BIIB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.110) is normal, around the industry mean (5.632). P/E Ratio (26.955) is within average values for comparable stocks, (48.974). BIIB's Projected Growth (PEG Ratio) (8.807) is slightly higher than the industry average of (3.004). Dividend Yield (0.000) settles around the average of (0.161) among similar stocks. P/S Ratio (3.181) is also within normal values, averaging (3.643).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.

View a ticker or compare two or three
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

BIIB is expected to report earnings to rise 34.77% to $4.07 per share on July 31

Biogen BIIB Stock Earnings Reports
Q2'25
Est.
$4.07
Q1'25
Beat
by $0.06
Q4'24
Beat
by $0.03
Q3'24
Beat
by $0.31
Q2'24
Beat
by $1.27
The last earnings report on May 01 showed earnings per share of $3.02, beating the estimate of $2.96. With 991.43K shares outstanding, the current market capitalization sits at 31.34B.
A.I. Advisor
published General Information

General Information

a manufacturer of therapies for people living with neurological, autoimmune and hematologic disorders

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Biotechnology
Address
225 Binney Street
Phone
+1 617 679-2000
Employees
7570
Web
https://www.biogen.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
AMZA42.970.21
+0.48%
InfraCap MLP ETF
IHDG45.750.18
+0.39%
WisdomTree Intl Hdgd Qual Div Gr ETF
MVFD26.580.07
+0.26%
Monarch Volume Factor Dividend Tree ETF
KTBA20.560.01
+0.05%
Structured Products Corp.
OCTJ23.91-0.03
-0.13%
Innovator Premium Income 30 Bar ETF Oct

BIIB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AMGN. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AMGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
+1.74%
AMGN - BIIB
56%
Loosely correlated
+1.30%
PFE - BIIB
50%
Loosely correlated
+0.86%
SNY - BIIB
46%
Loosely correlated
+1.04%
NVS - BIIB
44%
Loosely correlated
+0.64%
MRK - BIIB
44%
Loosely correlated
+0.37%
More